Health-Related Quality of Life and Functional Outcomes from a Randomized, Controlled Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention Deficit Hyperactivity Disorder
Tobias Banaschewski, Cesar Soutullo, Michel Lecendreux, Mats Johnson, Alessandro Zuddas, Paul Hodgkins, Ben Adeyi, Liza A Squires, David Coghill
CNS DRUGS | ADIS INT LTD | Published : 2013
This study was supported by funding from Shire Pharmaceuticals. Shire develops and markets drugs to treat psychiatric disorders, including ADHD.T. Banaschewski, D. Coghill, M. Johnson, M. Lecendreux, C. Soutullo and A. Zuddas were principal investigators in this clinical study. P. Hodgkins and L. Squires contributed to the study design. B. Adeyi was responsible for the statistical analysis. All authors were involved in discussion and interpretation of the data, critically revised the article and approved the manuscript before submission. Drs E. Southam and M. Cottingham of Oxford PharmaGenesis (TM) Ltd were funded by Shire to provide writing support, including editorial assistance, collation of the authors' comments and editing of the manuscript for submission.